The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study

• Published in: Alzheimer's research & therapy 2020-05, Vol.12 (1), p.51-51, Article 51
• Main Authors: Machado, Alejandra, Ferreira, Daniel, Grothe, Michel J, Eyjolfsdottir, Helga, Almqvist, Per M, Cavallin, Lena, Lind, Göran, Linderoth, Bengt, Seiger, Åke, Teipel, Stefan, Wahlberg, Lars U, Wahlund, Lars-Olof, Westman, Eric, Eriksdotter, Maria
• Format: Article
• Language: English
• Subjects: Advertising executives; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Alzheimer's disease; Analysis; Atrophy; Atrophy - pathology; Basal forebrain; Brain research; Care and treatment; Cholinergic Agents; Dementia; Growth factors; Heterogeneity; Hippocampus - diagnostic imaging; Hippocampus - pathology; Humans; Magnetic Resonance Imaging; Medical research; Medicin och hälsovetenskap; Nerve growth factor; Structural MRI; Subtypes; Target marketing
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-020-00620-7

The heterogeneity within Alzheimer's disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD and explored the relevance of subtype stratification in a small clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain. Structural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy-verified AD patients with structural MRI data at baseline and at 6- or 12-month follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach. All AD subtypes showed reduced basal forebrain volume as compared with the healthy controls. The limbic-predominant subtype showed the fastest basal forebrain atrophy rate, whereas the minimal atrophy subtype did not show any significant volume decline over time. Atrophy rates of the hippocampus and precuneus also differed across subtypes. Our preliminary data from the small NGF cohort suggest that the NGF treatment seemed to slow the rate of atrophy in the precuneus and hippocampus in some hippocampal-sparing AD patients and in one typical AD patient. The cholinergic system is differentially affected in distinct atrophy subtypes of AD. Larger studies in the future should confirm that this differential involvement of the cholinergic system may contribute to subtype-specific response to cholinergic treatment. Our preliminary findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratified by subtype. ClinicalTrials.gov identifier: NCT01163825. Registered 14 July 2010.